KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Idexx Laboratories (IDXX) Shares Outstanding (Diluted Average) (2016 - 2025)

Idexx Laboratories (IDXX) has 13 years of Shares Outstanding (Diluted Average) data on record, last reported at $81.0 million in Q4 2025.

  • For Q4 2025, Shares Outstanding (Diluted Average) fell 2.67% year-over-year to $81.0 million; the TTM value through Dec 2025 reached $81.0 million, down 2.67%, while the annual FY2025 figure was $81.0 million, 2.67% down from the prior year.
  • Shares Outstanding (Diluted Average) reached $81.0 million in Q4 2025 per IDXX's latest filing, roughly flat from $81.2 million in the prior quarter.
  • Across five years, Shares Outstanding (Diluted Average) topped out at $86.9 million in Q1 2021 and bottomed at $81.0 million in Q2 2025.
  • Average Shares Outstanding (Diluted Average) over 5 years is $84.1 million, with a median of $84.0 million recorded in 2023.
  • Peak YoY movement for Shares Outstanding (Diluted Average): rose 0.24% in 2021, then dropped 3.0% in 2022.
  • A 5-year view of Shares Outstanding (Diluted Average) shows it stood at $86.6 million in 2021, then fell by 2.28% to $84.6 million in 2022, then fell by 0.74% to $84.0 million in 2023, then fell by 0.87% to $83.2 million in 2024, then decreased by 2.67% to $81.0 million in 2025.
  • Per Business Quant database, its latest 3 readings for Shares Outstanding (Diluted Average) were $81.0 million in Q4 2025, $81.2 million in Q3 2025, and $81.0 million in Q2 2025.